AFTAT | “Animal-Free Testing for Acute Toxicity”

Summary
XCellR8 Limited aims to offer the first completely animal-free test for human acute toxicity. The primary focus is cosmetic product safety but the test may also later be applied to other industry sectors including household products, agrochemicals, medical devices and pharmaceuticals. In this context, animal-free means in vitro human cell culture based methods that do not utilise any animal-derived components. There are currently no validated in vitro tests for acute toxicity. Previous attempts to develop such tests used mouse cells and animal-derived components in the culture system and therefore still ultimately required the sacrifice of animals – an approach that is not considered acceptable by ethical cosmetic companies or by the public. The technological feasibility of the project has already been established, through existing tests of XCellR8’s internally developed proprietary methods. This feasibility assessment project is primarily required to address other practical, commercial, regulatory and financial aspects. It will also expand existing market research to assess the appetite of a greater cross-section of industry for such tests. During the project XCellR8 will investigate the alternative routes for test development and adoption by industry as a non-regulatory test to support product development. The ultimate objective is the international validation of the test and regulatory acceptance via incorporation into OECD Guidelines. The proposed project constitutes scientific advancement, using a fully human based method to assess human safety, as well as providing ethical, financial and commercial advantages over the use of animal tests. This offers true SME business model innovation, with an SME creating a pioneering solution that could bring a fundamental change to the manner in which cosmetic companies (and their suppliers) validate the safety of the ingredients used in their products.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/728993
Start date: 01-07-2016
End date: 31-12-2016
Total budget - Public funding: 71 429,00 Euro - 50 000,00 Euro
Cordis data

Original description

XCellR8 Limited aims to offer the first completely animal-free test for human acute toxicity. The primary focus is cosmetic product safety but the test may also later be applied to other industry sectors including household products, agrochemicals, medical devices and pharmaceuticals. In this context, animal-free means in vitro human cell culture based methods that do not utilise any animal-derived components. There are currently no validated in vitro tests for acute toxicity. Previous attempts to develop such tests used mouse cells and animal-derived components in the culture system and therefore still ultimately required the sacrifice of animals – an approach that is not considered acceptable by ethical cosmetic companies or by the public. The technological feasibility of the project has already been established, through existing tests of XCellR8’s internally developed proprietary methods. This feasibility assessment project is primarily required to address other practical, commercial, regulatory and financial aspects. It will also expand existing market research to assess the appetite of a greater cross-section of industry for such tests. During the project XCellR8 will investigate the alternative routes for test development and adoption by industry as a non-regulatory test to support product development. The ultimate objective is the international validation of the test and regulatory acceptance via incorporation into OECD Guidelines. The proposed project constitutes scientific advancement, using a fully human based method to assess human safety, as well as providing ethical, financial and commercial advantages over the use of animal tests. This offers true SME business model innovation, with an SME creating a pioneering solution that could bring a fundamental change to the manner in which cosmetic companies (and their suppliers) validate the safety of the ingredients used in their products.

Status

CLOSED

Call topic

SMEInst-05-2016-2017

Update Date

26-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.2. INDUSTRIAL LEADERSHIP
H2020-EU.2.3. INDUSTRIAL LEADERSHIP - Innovation In SMEs
H2020-EU.2.3.1. Mainstreaming SME support, especially through a dedicated instrument
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-1-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector